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Abstract
Introduction. When heart failure (HF) and atrial fibrillation (AF) afflict the same patient simultaneously, it becomes 
a challenge for cardiologists. This is not only due to the need to intensify preventive measures to reduce the prevalence 
of common aetiological factors, but also due to growing healthcare costs, particularly care costs for elderly patients at 
high risk of accumulated complications of both diseases. Our study was aimed at evaluating the concomitant incidence 
of AF on the natural history and treatment of Polish HF patients on the basis of data obtained in a multicentre registry 
study.
Material and methods. In this study, the population subjected to retrospective analysis consisted of Polish patients 
included in the long-term ESC-HF registry study (N = 1,126). A comparative analysis of the study group (AF+) and the 
control group (AF−) was carried out.
Results. No differences were observed in the rates of in-hospital deaths between the (AF+) and the (AF−) group: 2.9% 
versus 2.8%, [p = not significant (NS)]. The average duration of hospitalisation in the AF+ group was 9.8 ± 14.7 days 
compared to 8.8 ± 10.9 days in the AF− group (p = NS). In the AF+ group, compared to the AF− group, significantly higher 
frequencies were recorded for the following parameters: exacerbation of chronic HF as the cause of hospitalisation, in-
travenous diuretics usage during hospitalisation, electrical cardioversion, as well as in-hospital use of mineralocorticoid 
receptor antagonists, diuretics, digoxin, oral antithrombotic agents and amiodarone.
Conclusions. In the population of HF patients requiring hospitalisation, the AF+ subgroup is characterised by poorer 
clinical condition (biventricular cardiac decompensation, lower systolic blood pressure, higher heart rate on admission, 
and more frequent use of intravenous diuretics). The concomitance of AF significantly impacts the natural history and 
treatment of HF patients.
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one of the integral elements of an ESC research programme 
named EORP (the EURObservational Research Program-
me), initiated in 2008 as a continuation of the Euro Heart 
Survey concept that originated in 2000 [15].
The objective of EORP is to collect reliable up-to-date 
data on the most important cardiological heart problems 
of the 21st century so as to estimate their prevalence, pro-
gnosis and treatment, as well as to assess the complian-
ce of management routines with current ESC guidelines. 
During the long-term phase of the ESC-HF study, a total of 
12,240 patients treated at study sites across Europe was 
enrolled, including 7,401 patients treated in outpatient 
settings (59.5%) and 5,039 (40.5%) hospitalised patients 
[16]. The ESC-HF study was carried out according to a pro-
spective and observational design. In this study, the po-
pulation subjected to retrospective analysis consisted of 
Polish patients included in the long-term ESC-HF registry 
study (N = 1,126), corresponding to 9.1% of the entire re-
gistry population. HF patients treated in outpatient settings 
accounted for 32.1% of the study group (N = 361), while the 
remaining patients (67.9%, N = 765) were enrolled during 
hospitalisation due to newly diagnosed decompensated HF 
or exacerbation of chronic HF (patients with acute HF) or 
due to other causes. All patients (N = 1,126) were asses-
sed in terms of AF prevalence: the criterion for a diagnosis 
of arrhythmia was defined as a history of AF regardless of 
its form (paroxysmal, sustained, or chronic) and/or electro-
cardiographic (ECG) documentation of an AF episode (res-
ting or Holter ECG records) at the enrollment visit (outpa-
tients) or during hospitalisation. A comparative analysis 
of the study group (AF+) and the control group (AF−) was 
carried out in terms of clinical characteristics and natural 
history in case of hospitalised patients (i.e. comparisons 
of clinical parameters measured at admission and dischar-
ge, analysis of in-hospital deaths). Parameters related to 
natural history were compared between the study and the 
control group only in the subpopulation of hospitalised HF 
patients. This was because the inpatient setting allowed 
for the assessment of selected parameters at admission, 
during treatment, and upon discharge. The statistical signi-
ficance level was established at p < 0.05 for all tests. Sta-
tistical analysis was performed using MedCalc Statistical 
Software version 15.11.4.
Results
All patients were divided according to their AF status 
regardless of the time and form of prevalence: the study 
group AF+ (N = 521, 46.3% of all patients), and the control 
group AF− (N = 605, 53.7%). The hospitalisation rate was 
significantly higher in the AF+ group compared to the AF− 
group (72.6% vs. 64.0% of all patients, p = 0.0026). In 
the population of hospitalised patients (N = 765), in which 
the impact of concomitant AF on the natural history and 
Introduction
Atrial fibrillation (AF) is a subtype of supraventricular 
arrhythmia characterised by disordered activation of car-
diac atria that results in the impairment of their mechanical 
function [1]. AF is one of the most common arrhythmias 
encountered by clinicians in everyday practice. AF is as-
sociated with an elevated risk of brain stroke [2], heart 
failure (HF), and death [3, 4]. Due to difficulties in the 
selection of appropriate treatment, and thus in achieving 
desired outcomes, AF constitutes a significant clinical 
problem. Management in AF involves the prevention of 
thromboembolic events, appropriate control of heart rate 
to reduce the risk of tachycardia-induced cardiomyopathy, 
and correction of arrhythmia by attempts to restore and 
maintain sinus rhythm. The incidence of AF increases with 
age and amounts to about 0.5% in subjects in their 50s, 
3–5% in subjects aged over 65, and nearly 10% in subjects 
aged over 80 [5, 6]. In Poland, AF affects about 500,000 
individuals [7]. AF increases the risk of death by a factor 
of 1.5 in men and 1.9 in women [8].
The incidence of HF in the overall population is compa-
rable to the incidence of AF (2% in developed countries) and 
is likewise characterised by an increasing trend [9]. Accor-
ding to estimates, HF affects about 600,000 individuals in 
Poland [10]. Frequently encountered common aetiological 
factors such as obesity, arterial hypertension and diabetes 
increase the risk of new HF and AF cases, including cases 
where both these disorders occur simultaneously. Impor-
tantly, the incidence of both disorders is additionally incre-
ased by the fact that HF and AF are interrelated by means 
of a pathogenetic ‘vicious circle’, wherein isolated onset 
of one of these disorders can lead to development of the 
other [11, 12]. Pharmacoeconomic analyses are indicati-
ve of progressively increasing healthcare costs related to 
the diagnostics and treatment of concomitant HF with AF 
and complications thereof [13].
Therefore, concomitance of HF and AF becomes a chal-
lenge for cardiologists not only due to the need to intensify 
preventive measures to reduce the prevalence of common 
aetiological factors, but also due to growing healthcare 
costs, particularly care costs for elderly patients at high 
risk of accumulated complications of both diseases, in-
cluding permanent disability due to severe HF, and throm-
boembolic complications in the natural history of AF [14].
Our main objective consisted in the evaluation of the 
influence of concomitant AF on the natural history and tre-
atment of Polish HF patients on the basis of data obtained 
in a multicentre registry study.
Material and methods
The European Society of Cardiology (ESC) registry study in 
HF patients (ESC-HF Long-term Registry) was designed as 
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treatment of HF was evaluated, patients with confirmed 
AF (AF+) accounted for 49.4% of the population (N = 378). 
Clinical characteristics of the population of Polish HF pa-
tients enrolled into the registry while hospitalised are set 
out in Table 1.
In the AF+ group, compared to the AF− group, signifi-
cantly higher frequencies were recorded for the following 
parameters: exacerbation of chronic HF as the primary 
cause of hospitalisation, intravenous diuretics being used 
during hospitalisation, electrical cardioversion for any type 
of arrhythmia or AF, as well as in-hospital use of minera-
locorticoid receptor antagonists (MRA), diuretics, digoxin, 
oral antithrombotic agents, and amiodarone (see results 
in Table 2).
In the AF− group, compared to the AF+ group, signifi-
cantly higher frequencies were recorded for the following 
parameters: newly diagnosed HF, admission due to acute 
coronary syndrome (ACS) or ventricular arrhythmias, intra-
venous administration of nitrates during hospitalisation, 
coronary angiography and revascularisation during hospi-
talisation, as well as the use of statins and antiplatelet 
drugs (see results in Table 2).
The two groups did not differ significantly in terms of 
the incidence of HF as the primary reason for hospitali-
sation, the use of pressor amines during hospitalisation, 
the frequency of invasive electrophysiological procedures, 
percutaneous ablation, and implantation of electrothera-
peutic devices during hospitalisation, as well as in history 
of angiotensin-converting enzyme (ACE) inhibitors, angio-
tensin II receptor blockers (ARB), and beta-blockers (BB). 
Notably, the design of the form used in the ESC registry 
trial allowed for more than one cause for hospitalisation 
to be given, for example in cases of acute coronary syndro-
me with heart failure complication (see results in Table 2).
In the population of hospital patients, biventricular HF 
was the most common clinical form of HF in both the AF+ 
and the AF− group (74.6% vs. 62.5% compared to 68.5% 
in the entire population of hospitalised patients). The re-
maining clinical forms of HF (ACS-related decompensation 
of HF, HA, cardiogenic pulmonary oedema, right-ventricular 
HF, cardiogenic shock) were less common. No statistical dif-
ferences were observed between the AF+ and AF− groups 
with the exception of the incidence of ACS (13.7% in the AF− 
compared to 5.3% in the AF+ group, p < 0.0001; Figure 1).
The average duration of hospitalisation in the AF+ group 
was 9.8 ± 14.7 days compared to 8.8 ± 10.9 days in the 
AF− group [p = not significant (NS)]. In addition, the New 
York Heart Association (NYHA) class clinical status was 
compared in patients of both groups at admission and dis-
charge. In the AF+ group, the average NYHA class score at 
admission was 3.2 ± 0.7 compared to 3.0 ± 0.8 in the AF– 
group (p < 0.0001). At discharge, the average NYHA class 
scores in both groups were 2.3 ± 0.6 vs. 2.3 ± 0.6, (p = NS). 
In the AF+ group, the average left ventricular ejection fra-
ction (LVEF) at admission was 37.2 ± 14.8%, compared to 
33.6 ± 14.1% in the AF– group (p = NS). At discharge, the 
average LVEF in both groups was 39.2 ± 15.2% vs. 35.7 
± 15.2% respectively, and the difference was statistically 
significant (p = 0.006).
In the AF+ group, the average systolic blood pressure 
(SBP) at admission was 127.8 ± 24.4 mm Hg compared 
to 130.3 ± 29.2 mm Hg in the AF– group (p < 0.0001). 
At discharge, the SBP values in both groups were 116.7 
± 14.1 vs. 118.7 ± 17.1 mm Hg, respectively (p < 0,0001). 
In the AF+ group, the average heart rate (HR) at admission 
was 93.8 ± 27.4 bpm compared to 81.4 ± 21.0 bpm in the 
AF– group (p < 0.0001). At discharge, the HR values were 
77.0 ± 18.0 vs. 72.3 ± 15.8 bpm, respectively (p < 0.0001). 
In the AF+ group, the average body mass at admission 
was 80.4 ± 16.8 kg compared to 80.4 ± 17.1 kg in the 
AF– group (NS). At discharge, the average body mass was 
77.8 ± 16.5 vs. 78.6 ± 16.8 kg, respectively (p < 0.0001). 
All the above results can be seen in Table 3.
Overall, a total of 68 episodes of restored sinus rhythm 
were observed during hospitalisation in the entire AF+ 
group (N = 378), including 54 (79.4%) cases of sponta-
neous restoration of sinus rhythm.
A total of 22 deaths (2.9%) occurred in the subpopu-
lation of hospitalised patients. No differences were ob-
served in the rates of in-hospital deaths between the AF+ 
(N = 11/378) and the AF− (N = 11/387) groups: 2.9% vs. 
2.8%, p = NS (Figure 2).
Discussion
After evaluating the results obtained in our retrospective 
analysis of data collected in Polish patients included in 
the ESC-HF registry, we conclude that concomitance of AF 
Table 1. Clinical characteristics of Polish heart failure (HF)  
inpatients in multicentre European Society of Cardiology (ESC) 
registry
Variable Value
Number of hospitalised patients 765
Age [years], median 67
Gender — female [%] 32.5
BMI [kg/m2], median 27.7
LVEF [%], median 34.0
LVEF > 45% [%], (HFpEF) 23.5
NYHA class III–IV [%] 76.8
Ischaemic HF [%] 55.3
Brain stroke/TIA [%] 11.0
AF [%] 49.4
BMI — body mass index; LVEF — left ventricular ejection fraction; HFpEF — heart failure with pre-
served ejection fraction; NYHA — New York Heart Association; TIA — transient ischaemic attack; 
AF — atrial fibrillation
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incidence of advanced HF of more than six months’ dura-
tion in the medical history. So far as admission reasons 
other than AF were concerned, acute coronary syndrome, 
myocardial infarction, and ventricular arrhythmias were 
more common in the AF− group. In the study by Ozierań-
ski et al. [17], patients without AF were also more frequ-
ently admitted to hospital due to ACS. In this study, AF was 
present in 49.4% of hospitalised HF patients compared to 
41.4% of patients in the study by Ozierański et al. Patients 
from the AF+ group were characterised by a significantly 
significantly impacts the natural history and treatment of 
HF patients.
Our study showed that in both subgroups of patients 
hospitalised in the course of HF with or without AF, clinical 
improvement was achieved as the result of hospital treat-
ment. The coincidence of AF had no significant impact on 
in-hospital mortality rates (2.9% vs. 2.8%).
In the subgroup of AF+ patients, significantly higher 
incidence was observed for exacerbations of previously 
diagnosed chronic HF; this was associated with a higher 
Table 2. Comparison of selected factors related to course of hospitalisation in study group (AF+) and control group (AF−)
Factors [%] (N) AF+ 
N = 378
AF− 
N = 387
p 
AF+ vs. AF−
Acute HF de novo 9.8% (37) 19.1% (74) 0.0004
Chronic HF exacerbation 90.2% (341) 80.95% (313) 0.0004
Reason for hospitalisation
HF 89.2% (337) 86.0% (333) NS
ACS/MI 16.1% (61) 28.7% (111) < 0.0001
Ventricular arrhythmia 7.1% (27) 13.2% (51) 0.0083
Intravenous drugs during hospitalisation
Dopamine 6.3% (24) 5.7% (22) NS
Dobutamine 6.3% (24) 6.7% (26) NS
Nitrates 9.5% (36) 15.0% (58) 0.0284
Diuretics 64.3% (243) 51.4% (199) 0.0004
Invasive procedures during hospitalisation
Coronarography 19.0% (72) 33.9% (131) < 0.0001
Coronary revascularisation 8.5% (32) 15.5% (60) 0.036
Invasive electrophysiological exam 1.1% (4) 0.8% (3) NS
Ablation 1.6% (6) 0.8% (3) NS
Electric cardioversion 3.7% (14) 1.0% (4) 0.0284
AF cardioversion 3.7% (14) 0.0% (0) 0.0004
CRT implantation 6.1% (23) 7.0% (27) NS
ICD implantation 12.7% (48) 17.1% (66) NS
Pharmacotherapy during hospitalisation
ACE inhibitors 71.2% (269) 75.7% (293) NS
ARB 9.3% (35) 10.9% (42) NS
Beta-blockers 89.2% (337) 87.6% (339) NS
MRA 71.7% (271) 61.0% (236) 0.0022
Diuretics 89.9% (340) 78.6% (304) < 0.0001
Digoxin 34.4% (130) 11.4% (44) < 0.0001
Statins 62.4% (236) 70.5% (273) 0.0215
Antiplatelets drugs 42.3% (160) 76.2% (295) < 0.0001
Oral anticoagulants 75.1% (284) 16.5% (64) < 0.0001
Amiodarone 17.2% (65) 9.6% (37) 0.0027
N — number of patients; AF — atrial fibrillation; HF — heart failure; NS — not significant; ACS — acute coronary syndrome; MI — myocardial infarction; CRT — cardiac resynchronisation therapy; ICD — implantab-
le cardioverter-defibrillator; ACE — angiotensin-converting enzyme; ARB — angiotensin II receptor blockers; MRA — mineralocorticoid receptor antagonist
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higher frequency of used intravenous diuretics. This reflec-
ted a higher incidence of decompensated biventricular HF, 
whereas patients from the AF− group were characterised 
by a significantly higher frequency of applied intravenous 
nitrates due to a higher frequency of episodes of myocar-
dial ischaemia, coronary disease and ACS as a reason for 
hospitalisation in the study population. No differences were 
observed with regard to the frequency of pressor amines 
being used in hospital management of decompensated, 
advanced HF in both study groups.
In the AF+ group, significantly higher frequency of elec-
trical cardioversion procedures was observed regardless of 
the type of arrhythmia, although the outcomes were largely 
affected by the fact that all cardioversion procedures due 
to AF were performed in this subgroup of patients. On the 
other hand, in the AF− group, higher frequency of corona-
ry angiography and revascularisation was observed since 
ACS were a more com mon cause of hospitalisations. As 
part of oral pharmacotherapy, the AF+ group was charac-
terised by a higher use of aldosterone antagonists, loop 
Table 3. Comparison of selected clinical parameters in study group (AF+) and control group (AF−)
Group AF+ 
N = 378
AF− 
N = 387
AF+ vs. AF− 
p
Duration of hospitalisation [days], mean ± SD 9.8 ± 14.7 8.8 ± 10.9 NS
NYHA class at admission, mean ± SD 3.2 ± 0.7 3.0 ± 0.8 p < 0.0001
NYHA class at discharge, mean ± SD 2.3 ± 0.6 2.3 ± 0.6 NS
LVEF [%] at admission, mean ± SD 37.2 ± 14.8 33.6 ± 14.1 NS
LVEF [%] at discharge, mean ± SD 39.2 ± 15.2 35.7 ± 15.2 p = 0.006
SBP [mm Hg] at admission, mean ± SD 127.8 ± 24.4 130.3 ± 29.2 p < 0.0001
SBP [mm Hg] at discharge, mean ± SD 116.7 ± 14.1 118.7 ± 17.1 p < 0.0001
HR [bpm] at admission, mean ± SD 93.8 ± 27.4 81.4 ± 21.0 p < 0.0001
HR [bpm] at discharge, mean ± SD 77.0 ± 18.0 72.3 ± 15.8 p < 0.0001
Body mass at admission, mean ± SD 80.4 ± 16.8 80.4 ± 17.1 NS
Body mass at discharge, mean ± SD 77.8 ± 16.5 78.6 ± 16.8 p < 0.0001
AF — atrial fibrillation; N — number of patients; SD — standard deviation; NS — not significant; NYHA — New York Heart Association; LVEF — left ventricular ejection fraction; SBP — systolic blood pressure;  
HR — heart rate   
Figure 1. Clinical form of heart failure (HF) on admission to hospital; N — number of patients; ACS — acute coronary syndrome; MI — myo-
cardial infarction
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diuretics, amiodarone, digoxin, and oral anticoagulants 
(due to more advanced HF at admission, worse clinical 
performance status of patients, the presence of AF, and 
the requirement to control rhythm rate or rhythm after car-
dioversion), whereas the AF− group was characterised by 
a higher use of statins and anticoagulants (again due to 
the effects of coronary heart disease and the frequency of 
ACS as the cause of hospitalisation).
On the other hand, no differences were observed with 
regard to the use of basic drugs applied in the treatment 
of HF and which have a proven positive impact on the pro-
gnosis, such as ACE inhibitors, angiotensin II receptor an-
tagonists (sartans) as well as beta-blockers. These drugs 
were used in more than 80% of patients in both groups, 
regardless of AF status. No significant differences were 
also observed with regard to the frequency of electrothe-
rapeutic procedures [implantable cardioverter-defibrillator 
(ICD) and cardiac resynchronisation therapy (CRT) implan-
tations] in the treatment of HF.
No significant difference was observed in the duration 
of hospitalisation, and clinical improvement was achieved 
in both groups. NYHA class was higher at admission than 
at discharge in both groups. Patients in the AF− group were 
characterised by higher SBP values compared to the AF+ 
group (haemodynamic impact of tachycardia on hypoten-
sion). SBP was found to be lower at discharge compared 
to admission (impact of initial doses of drugs in HF combi-
nation treatment during hospitalisation).
No differences were observed between the groups in 
terms of patient body mass on admission undergoing a sig-
nificant reduction at discharge. This might be due to the 
high frequency of biventricular HF in both study groups. Pa-
tients required combination compensatory treatment, in-
cluding intensive diuretic treatment, which led to reduced 
retention of fluids, reduced body mass, and reduced arterial 
pressure. In the AF+ group, the heart rate on admission was 
significantly higher than in the AF− group (93.8 ± 27.4 vs. 
81.4 ± 21.0, p < 0.0001). Reduction in heart rates was 
achieved in both groups at discharge, with heart rate con-
trol level in the AF+ group (mean HR 77 bpm) meeting the 
recommended level set out in guidelines [1, 18], as oppo-
sed to the AF− group where target heart rate value was not 
achieved (mean HR 72 bpm) [9].
Upon admission, both groups were characterised by si-
milar LVEF values (mean LVEF 37.2% vs. 33.6%). No signifi-
cant increase in LVEF values was achieved upon discharge 
in either group. This might have been due to the short pe-
riod between echocardiographic examinations of patients 
with moderate reduced ejection fraction in the majority of 
cases. Patients with HF need at least three months of op-
timal pharmacological treatment to improve left ventricle 
systolic function significantly. In this study, treatment of 
AF+ patients was based on rhythm control strategy in 17% 
of cases, mainly cases of spontaneous restoration of si-
nus heart rhythm. However, ablation procedures used to 
eliminate the basis of supraventricular arrhythmias, inclu-
ding AF, were not taken into account due to sparse data 
confirming that such procedures had indeed been perfor-
med. In light of the AATAC-AF (Ablation vs. Amiodarone for 
Treatment of Atrial Fibrillation in Patients With Congestive 
Heart Failure and Implanted ICD/CRT-D) study, in the popu-
lation of patients with heart failure with reduced ejection 
fraction (HFrEF) and symptomatic, sustained AF, ablation 
of arrhythmia is more effective and safer than amiodarone 
treatment — during 26 months of follow-up, no recurrence 
of arrhythmia was observed in 70% of patients (compared 
to 34% of patients in the amiodarone group). In addition, 
the incidence of hospitalisations and deaths was also lo-
wer, provided that the procedure had been performed in 
a safe manner by experienced staff. The lack of benefits 
in the amiodarone group was associated with the adverse 
effects of the drug [19]. The relatively low contribution of 
rhythm control strategies to overall treatment in this study 
compared to findings published by Sosnowska-Pasiarska 
et al. [20] in 2010 is indicative of a trend towards ventri-
cular rate control strategies becoming more common. In 
the population of Polish patients enrolled in the pilot pha-
se of the ESC-HF Registry study, AF was present in 40% 
of patients on admission compared to 27% on discharge. 
However, it should be highlighted that in the population 
presented in our study, being much larger than that in the 
pilot phase of the registry study, the in-hospital mortality 
rate was 2.9% and this was lower than in the reference 
study (3.8%).
Thus, it appears that the choice of the strategy rhythm 
control vs the rate control in AF patients had no impact 
upon in-hospital survival of patients in the study popula-
tion. In the analysis of heart rhythm on discharge in the 
AF+ group (data available for N = 374 patients), AF was 
still present in 58.3% of patients, which means that near-
ly 60% of patients received medications to control ventri-
cular rate in AF upon being discharged. In 11.5% of cases, 
Figure 2. In-hospital deaths in study group (AF+) and control group 
(AF−); AF — atrial fibrillation
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the predominant rhythm at discharge was identified as the 
pacemaker rhythm, despite the fact that all patients had 
AF in their medical histories.
Conclusions
In the population of HF patients requiring hospitalisation, 
the AF+ subgroup is characterised by worse clinical condi-
tion (more common symptoms of cardiac decompensation, 
mostly biventricular, lower systolic blood pressure, higher 
heart rate on admission, and more frequent use of intra-
venous diuretics). No differences were observed between 
groups regarding the duration of hospitalisation or the 
frequency of pressor amines being used during hospitali-
sation. Moreover, arrhythmia had no impact on in-hospital 
mortality rates.
In the group of HF and AF patients, the most common 
strategy to control heart rate consists of the administra-
tion of BB and digoxin. Less commonly, rhythm is controlled 
by amiodarone as a means to prevent the recurrence of 
arrhythmia. The choice of the management strategy to be 
pursued during hospitalisation is associated, among others, 
with the high percentage of patients with permanent AF.
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Streszczenie
Wstęp. Współwystępowanie niewydolności serca (HF) i migotania przedsionków (AF) staje się wyzwaniem dla kardiologii 
nie tylko ze względu na konieczność intensyfikacji działań prewencyjnych w kierunku ograniczenia rozpowszechnienia 
wspólnych czynników etiologicznych, lecz również z powodu rosnących kosztów opieki nad głównie starszymi pacjenta-
mi obciążonymi wysokim ryzykiem skumulowanych powikłań obu chorób, w tym trwałej niepełnosprawności z powodu 
ciężkiej HF i powikłań zakrzepowo-zatorowych w przebiegu AF.
Głównym celem pracy była ocena wpływu współwystępowania AF na przebieg kliniczny oraz leczenie polskich pacjentów 
z HF na podstawie danych z wieloośrodkowego badania rejestrowego.
Materiał i metody. Populacja poddana retrospektywnej analizie w prezentowanej pracy obejmowała polskich pacjentów 
włączonych do Rejestru Niewydolności Serca ESC w trakcie fazy długoterminowej (n = 1126). Przeprowadzono analizę 
porównawczą grupy badanej (AF+) i grupy kontrolnej (AF–).
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Wyniki. Nie stwierdzono różnic w częstości zgonów wewnątrzszpitalnych między grupami AF+ oraz AF–: 2,9% w porów-
naniu z 2,8% (p = nieistotne [NS]). Średni czas hospitalizacji w grupie AF+ wynosił 9,8 ± 14,7 dnia w porównaniu z 8,8 
± 10,9 w grupie AF– (p = NS). W grupie AF+ w porównaniu z grupą AF– istotnie częściej: zaostrzenie przewlekłej HF 
występowało jako przyczyna hospitalizacji, podczas hospitalizacji stosowano leki moczopędne dożylnie, wykonywano 
kardiowersję elektryczną, a także istotnie częściej stosowano w trakcie hospitalizacji antagonistów receptorów minera-
lokortykoidowych, diuretyki, digoksynę, doustne leki przeciwzakrzepowe oraz amiodaron.
Wnioski. W populacji chorych z HF wymagających hospitalizacji podgrupa z AF charakteryzuje się gorszym stanem 
klinicznym (częściej występujące objawy dekompensacji układu krążenia, głównie obukomorowej, niższe ciśnienie skur-
czowe, wyższa częstość rytmu serca przy przyjęciu oraz częstsze stosowanie diuretyków dożylnie). Współwystępowanie 
AF istotnie wpływa na przebieg kliniczny oraz leczenie pacjentów z HF.
Słowa kluczowe: niewydolność serca, migotanie przedsionków, leczenie, wyniki kliniczne, rejestr
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